2600mg

It initially demonstrated the ability to mitigate age-related physical dysfunction in mice. This early research paved the way for several notable human clinical trials, beginning in 2019. It works by targeting adverse tyrosine kinases that are associated with aging.D+Q slows down (inhibits) these pathways, specificallyBCR-Abl ,SRC Family (SRC, LCK, HCK, FYN, YES, FGR, BLK, LYN, and FRK),c-KIT (PI3K, AKT, JAK2, STAT3, MAPK),CSF1R ,BCL-2 ,CDK2, andPDGFR (α and β).